Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BIO Generic Biologics Task Force Hopes To Complete Proposal In June

Executive Summary

A Biotechnology Industry Organization task force is developing a policy on generic biologics with the goal of presenting it to the BIO board ahead of the association's annual meeting at the end of June.

You may also be interested in...



Generic Biologics Commission Urged; McCain Abjures Bioterrorism Add-On

Sen. Jay Rockefeller (D-W.Va.) is expected to introduce legislation that would create a commission to examine the possibility of generic biologics

Generic Biologics Commission Urged; McCain Abjures Bioterrorism Add-On

Sen. Jay Rockefeller (D-W.Va.) is expected to introduce legislation that would create a commission to examine the possibility of generic biologics

BIO Generic Biologics Position: All Products Need "Rigorous" Clinical Trials

The Biotechnology Industry Organization position statement on generic biologics is firmly against any shortcuts to market for follow-on products.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS037944

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel